
Fig 1: NCAN-001 (GB1023)






Fig. 2: mRNA Expression profile of NCAN




Fig. 3: relative mRNA Expression profile of BIRC5




Fig.4a: gamma interferon-ELISpot
The presence of PSMA and Survivin-specific IFNγ-secreting $CD4^+$ T-cells in peripheral blood mononuclear cells (PBMC) from different time points of a vaccinated patient were determined using an IFNγ-EliSpot.




Fig.4b: gamma interferon-ELISpot
The presence of PSMA and Survivin-specific IFNγ-secreting $CD4^+$ T-cells in peripheral blood mononuclear cells (PBMC) from different time points of a vaccinated patient were determined using an IFNγ-EliSpot. Time points: pre-vaccination (a) and after 3.(b), 6.(c), 7.(d), 8.(e), 9.(f), 10.(g), 11.(h) vaccination.




Fig.5: Intracellular staining-Assay (ICS) - The presence of Survivin-specific IFNγ-, IL-5, IL-10, TNFα-secreting $CD4^+$ T-cells in PBMC from three different time points of a vaccinated patient were determined via ICS-Assay. Time points: after 1.(a), 3.(b), 7.(c), vaccination.




Fig. 6 PSA stability with no rise greater than 10% from baseline PSA




Figure 7. PSA DT increase without PSA stability




Figure 8. No change of PSA DT in months during vaccination, but decline afterwards




Figure 9. No change of PSA DT during vaccination




Figure 10. No change of PSA DT during vaccination




Figure 11. Interim PSA decline or DT increase followed by DT decrease
Figure legend: circle: PSA value prior or after vaccination; dot: PSA value at each vaccination; broken line R: interval of external radiotherapy broken line H: interval of intermittent hormone therapy; broken line C: interval of taxotere chemotherapy



PMA / Ionomycin
Survivin (II)
PSMA (II)
SSC-H
FSC-H
CD4
FL4-H
FL3-H
IFNg
FL1-H
82%
0,1%
93%
CD8
CD4

Figure 12.



IFNγ
TNFα
IL-2
CD107a
CD154
DC + RAP80 Protein
DC + Survivin Protein
DC + HIV Peptid
DC + Surv Peptid
CD4

Figure 13.




Figure 14. Multifunctional $CD4^+$ T cells - Pro10 11.V




Figure 14 (continued)

Figure 15.

	HLA class II typing of cell lines	Pro26 (**DR1**,DR13,DRB3, DQ5, DQ6)	Pro15 (**DR1**, **DR11**, DRB3, DQ3, DQ5)
AL	DR1, DQ1	+++	+++
LAM	DQ3, DR4, DP4, DQA1*03	-	-
HO301	DQ5, DR6, DP19	+++	++
BM15	DR11, DRB3, DQ3	+++	+
MGAR	DQ6, DR15, DP4, DW2	-	-
LG2-EBV	DQ5, DRB3, DR14, DR7, DQB1*02	n.t.	n.t.
EMJ	DR13, DQ1, DP3,4, DW19	n.t.	n.t.

TNFa responses: (-) < 0,1% CD4+, (+) > 3x control, (++) > 5x control, (+++) > 10x control